• 1
    Fasco MJ, Principe LM, Walsh WA, Friedman PA. Warfarin inhibition of vitamin K 2,3-epoxide reductase in rat liver microsomes. Biochemistry 1983; 22: 565560.
  • 2
    Cambell HARW, Smith WK, Link KP. Studies on the hemorrhagic sweet clover disease. IV. The isolation and crystallization of the hemorrhagic agent. J Biol Chem 1941; 138: 2133.
  • 3
    Kirkwood TB. Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb Haemost 1983; 49: 23844.
  • 4
    Haemostasis and Thrombosis Task Force. Guidelines on oral anticoagulation, 2nd edn. British Society for Haematology. British Committee for Standards in Haematology. J Clin Pathol 1990; 43: 17783.
  • 5
    Poller L, Van Den Besselaar AM, Jespersen J, Tripodi A, Houghton D. The European Concerted Action on Anticoagulation (ECAA): field studies of coagulometer effects on the ISI of ECAA thromboplastins. Thromb Haemost 1998; 80: 61523.
  • 6
    WHO Expert Committee on Biological Standardization: 28th Report. World Health Organ Tech Rep Ser 1977; 610: 1133.
  • 7
    Lindahl TL, Egberg N, Hillarp A, Odegaard OR, Edlund B, Svensson J, Sandset PM, Ranby M. INR calibration of Owren-type prothrombin time based on the relationship between PT% and INR utilizing normal plasma samples. Thromb Haemost 2004; 91: 122331.
  • 8
    Hillarp A, Egberg N, Nordin G, Stigendal L, Fagerberg I, Lindahl TL. Local INR calibration of the Owren type prothrombin assay greatly improves the intra- and interlaboratory variation. A three-year follow-up from the Swedish national external quality assessment scheme. Thromb Haemost 2004; 91: 3007.
  • 9
    Quick A. The prothrombin time in hemophilia and in obstructive jaundice. J Biol Chem 1935; 109: 734.
  • 10
    Owren PA, Aas K. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand J Clin Lab Invest 1951; 3: 2018.
  • 11
    Owren PA. Thrombotest. A new method for controlling anticoagulant therapy. Lancet 1959; 2: 7548.
  • 12
    Quick A, Stanley-Brown M, Bancroft F. A study of the coagulation defect in hemophilia and jaundice. Am J Med Sci 1935; 190: 50111.
  • 13
    Britt RP, James AH, Raskino CL, Thompson SG. Factors affecting the precision of warfarin treatment. J Clin Pathol 1992; 45: 10036.
  • 14
    Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A, Roitelman J, Harats D, Halkin H, Ezra D. Interindividual variability in sensitivity to warfarin – nature or nurture? Clin Pharmacol Ther 2001; 70: 15964.
  • 15
    Shikata E, Ieiri I, Ishiguro S, Aono H, Inoue K, Koide T, Ohgi S, Otsubo K. Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 2004; 103: 26305.
  • 16
    Voora D, Eby C, Linder MW, Milligan PE, Bukaveckas BL, McLeod HL, Maloney W, Clohisy J, Burnett RS, Grosso L, Gatchel SK, Gage BF. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost 2005; 93: 7005.
  • 17
    Loebstein R, Vecsler M, Kurnik D, Austerweil N, Gak E, Halkin H, Almog S. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. Clin Pharmacol Ther 2005; 77: 36572.
  • 18
    Lindh JD, Lundgren S, Holm L, Alfredsson L, Rane A. Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clin Pharmacol Ther 2005; 78: 54050.
  • 19
    Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ, Lappegard K, Seifried E, Scharrer I, Tuddenham EG, Muller CR, Strom TM, Oldenburg J. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427: 53741.
  • 20
    Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. Identification of the gene for vitamin K epoxide reductase. Nature 2004; 427: 5414.
  • 21
    Harrington DJ, Underwood S, Morse C, Shearer MJ, Tuddenham EG, Mumford AD. Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1. Thromb Haemost 2005; 93: 236.
  • 22
    Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 228593.
  • 23
    Reitsma PH, Heijden JF, Groot AP, Rosendaal FR, Buller HR. A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med 2005; 2: e312.
  • 24
    Wadelius M, Chen LY, Downes K, Ghori J, Hunt S, Eriksson N, Wallerman O, Melhus H, Wadelius C, Bentley D, Deloukas P. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005; 5: 26270.
  • 25
    D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105: 6459.
  • 26
    Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seifried E, Muller CR, Wienker TF, Oldenburg J. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 2005; 94: 7739.
  • 27
    Boyle CM. Case of apparent resistance of Rattus norvegicus Berkenhout to anticoagulant poisons. Nature (London) 1960; 188: 517.
  • 28
    Tie JK, Nicchitta C, Von Heijne G, Stafford DW. Membrane topology mapping of vitamin K epoxide reductase by in vitro translation/cotranslocation. J Biol Chem 2005; 280: 164106.
  • 29
    Veenstra DL, You JH, Rieder MJ, Farin FM, Wilkerson HW, Blough DK, Cheng G, Rettie AE. Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics 2005; 15: 68791.
  • 30
    Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG, Pengo V, Barban M, Padrini R, Ieiri I, Otsubo K, Kashima T, Kimura S, Kijima S, Echizen H. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 2006; 16: 10110.
  • 31
    Penrod LE, Allen JB, Cabacungan LR. Warfarin resistance and enteral feedings: 2 case reports and a supporting in vitro study. Arch Phys Med Rehabil 2001; 82: 12703.
  • 32
    Greenblatt DJ, Von Moltke LL. Interaction of warfarin with drugs, natural substances, and foods. J Clin Pharmacol 2005; 45: 12732.
  • 33
    Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 232933.
  • 34
    Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, Charng MJ, Lu MJ, Hung CR, Wei CY, Chen CH, Wu JY, Chen YT. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005; 14: 174551.
  • 35
    Osman A, Arbring K, Lindahl TL. A new high-performance liquid chromatographic method for determination of warfarin enantiomers. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 826: 7580.